Alpha-glucosidase Inhibitors Market Size, Share & Trends Analysis Report By Disease Type (Type 2 Diabetes, Dumping Syndrome), By Application, By Region, And Segment Forecasts, 2023 - 2030

Alpha-glucosidase Inhibitors Market Trends

The global alpha-glucosidase inhibitors market size was estimated at USD 4.67 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 2.70% from 2023 to 2030. The market growth is fueled by the increasing prevalence of diabetes, growing demand for safe diabetes treatment, and increasing awareness of alpha-glucosidase inhibitors. Diabetes is a chronic condition that is becoming increasingly prevalent worldwide. Alpha-glucosidase inhibitors are a safe and effective way to manage blood sugar levels in people with type 2 diabetes. Furthermore, growing awareness of alpha-glucosidase inhibitors among healthcare professionals and patients is most likely to drive market growth.

According to an article published in the National Library of Medicine in June 2023, the occurrence of Dumping syndrome symptoms in patients who underwent gastric surgery is significant, affecting a substantial proportion, ranging from 20% to 50%. This high prevalence emphasizes the need for interventions to address the symptoms associated with Dumping syndrome in this specific patient population. Severe symptoms, witnessed in around 1% to 5% of these patients, further underscore the demand for alpha-glucosidase inhibitors market.

Furthermore, according to the National Library of Medicine article published in August 2022, alpha-glucosidase inhibitors represent a pharmaceutical class employed in managing type 2 diabetes mellitus either independently or in conjunction with other antidiabetic medications. Their application extends to patients with impaired glucose tolerance, contributing to the postponement of type 2 diabetes mellitus onset. This drug class proves advantageous for individuals at risk of hypoglycemia or lactic acidosis, making them viable alternatives to antidiabetic drugs like sulfonylureas and metformin. FDA approval further solidifies the role of Alpha-glucosidase inhibitors in addressing type 2 diabetes mellitus.

Disease Type Insights

On the basis of disease type, the alpha-glucosidase inhibitors market is segmented into type 2 diabetes and dumping syndrome. The type 2 diabetes segment held the largest market share in 2022. The increasing prevalence of diabetes in India underscores a substantial driver for the alpha-glucosidase inhibitors Market. According to the WHO, it is estimated that 77 million individuals aged 18 years and above have type 2 diabetes, and an additional 25 million are at a prediabetic stage. The urgent need for effective interventions fuels the market. Moreover, the significant proportion of individuals unaware of their diabetic status accentuates the importance of early detection and treatment, further propelling the demand for relevant therapies.

Distribution Channel Insights

Alpha-glucosidase inhibitors are considered one of the most effective medications to treat type 2 diabetes. They work by slowing down the digestive process of carbohydrates, which ultimately helps to regulate blood sugar levels. These drugs are not widely available over the counter and are usually only available through a prescription. The distribution channels for alpha-glucosidase inhibitors involve several stakeholders, including hospital, retail and online pharmacies. These distribution channels in tandem work together to ensure that patients receive the correct medication and dosage.

Regional Insights

North America dominated the market in 2022. However, Asia Pacific is expected to grow at the fastest CAGR for the forecast period.According to the CDC, in the U.S., affecting over 37 million individuals, this substantial prevalence of diabetes is a significant driver for the alpha-glucosidase inhibitors market in North America. Among these cases, approximately 90-95% are attributed to type 2 diabetes. This prevalence highlights the considerable demand for effective treatments, emphasizing the market's growth potential in addressing the therapeutic needs of individuals with type 2 diabetes.

Key Companies & Market Share Insights

Key players operating in the market are Bayer, Takeda, Pfizer, Glenmark, Sun Pharma, Torrent, Unichem, Hexalag, Eris, and Blue Cross. The healthcare industry is witnessing significant growth, and the market participants are leaving no stone unturned to capitalize on the opportunities. Companies are constantly investing in R&D, mergers and acquisitions, and other strategic alliances to gain new market avenues. The following are some instances of such initiatives:

• In September 2023, Amicus Therapeutics received FDA approval for Pombiliti (cipaglucosidase alfa-atga) plus Opfolda 65mg (miglustat) capsules. This dual-component therapy is designed for adults with Pompe disease (LOPD) weighing less than or equal to 40 kg who show no improvement with their latest enzyme replacement therapy (ERT). The late-onset Pompe disease, a rare and life-risking lysosomal disorder, results from the deficit of the alpha-glucosidase enzyme acid.

• In June 2022, the European Commission approved the marketing of an enzyme replacement therapy (ERT), Nexviadyme (avalglucosidase alfa), intended for the extended treatment of both infantile-onset and late-onset Pompe disease. This rare and progressive muscle disorder now has an approved medicine in Europe, marking the first such approval since 2006.